| Weight loss through lifestyle modification significantly reduces features of nonalcoholic steatohepatitis E Vilar-Gomez, Y Martinez-Perez, L Calzadilla-Bertot, A Torres-Gonzalez, ... Gastroenterology 149 (2), 367-378. e5, 2015 | 2281 | 2015 |
| The natural course of non-alcoholic fatty liver disease L Calzadilla Bertot, LA Adams International journal of molecular sciences 17 (5), 774, 2016 | 754 | 2016 |
| Fibrosis severity as a determinant of cause-specific mortality in patients with advanced nonalcoholic fatty liver disease: a multi-national cohort study E Vilar-Gomez, L Calzadilla-Bertot, VWS Wong, M Castellanos, ... Gastroenterology 155 (2), 443-457. e17, 2018 | 721 | 2018 |
| Mortality and complication rates of percutaneous ablative techniques for the treatment of liver tumors: a systematic review LC Bertot, M Sato, R Tateishi, H Yoshida, K Koike European radiology 21, 2584-2596, 2011 | 201 | 2011 |
| Clinical trial: a nutritional supplement Viusid, in combination with diet and exercise, in patients with nonalcoholic fatty liver disease E Vilar Gomez, A Rodriguez De Miranda, B Gra Oramas, E Arus Soler, ... Alimentary pharmacology & therapeutics 30 (10), 999-1009, 2009 | 136 | 2009 |
| The natural history of compensated HCV-related cirrhosis: a prospective long-term study EV Gomez, YS Rodriguez, LC Bertot, AT Gonzalez, YM Perez, EA Soler, ... Journal of hepatology 58 (3), 434-444, 2013 | 105 | 2013 |
| Diabetes impacts prediction of cirrhosis and prognosis by non‐invasive fibrosis models in non‐alcoholic fatty liver disease LC Bertot, GP Jeffrey, B de Boer, G MacQuillan, G Garas, J Chin, Y Huang, ... Liver International 38 (10), 1793-1802, 2018 | 104 | 2018 |
| Nonalcoholic fatty liver disease‐related cirrhosis is commonly unrecognized and associated with hepatocellular carcinoma LC Bertot, GP Jeffrey, M Wallace, G MacQuillan, G Garas, HL Ching, ... Hepatology communications 1 (1), 53-60, 2017 | 90 | 2017 |
| Development and validation of a noninvasive prediction model for nonalcoholic steatohepatitis resolution after lifestyle intervention E Vilar‐Gomez, A Yasells‐Garcia, Y Martinez‐Perez, L Calzadilla‐Bertot, ... Hepatology 63 (6), 1875-1887, 2016 | 75 | 2016 |
| Trends in hepatocellular carcinoma due to non-alcoholic fatty liver disease LC Bertot, LA Adams Expert review of gastroenterology & hepatology 13 (2), 179-187, 2019 | 72 | 2019 |
| Improvement in liver histology due to lifestyle modification is independently associated with improved kidney function in patients with non‐alcoholic steatohepatitis E Vilar‐Gomez, L Calzadilla‐Bertot, SL Friedman, B Gra‐Oramas, ... Alimentary pharmacology & therapeutics 45 (2), 332-344, 2017 | 72 | 2017 |
| Antioxidant and immunomodulatory effects of Viusid in patients with chronic hepatitis C EV Gomez, YM Perez, HV Sanchez, GR Forment, EA Soler, LC Bertot, ... World journal of gastroenterology: WJG 16 (21), 2638, 2010 | 68 | 2010 |
| Serum biomarkers can predict a change in liver fibrosis 1 year after lifestyle intervention for biopsy‐proven NASH E Vilar‐Gomez, L Calzadilla‐Bertot, SL Friedman, B Gra‐Oramas, ... Liver International 37 (12), 1887-1896, 2017 | 66 | 2017 |
| Type 2 diabetes and metformin use associate with outcomes of patients with nonalcoholic steatohepatitis–related, Child–Pugh A cirrhosis E Vilar-Gomez, L Calzadilla-Bertot, VWS Wong, M Castellanos, ... Clinical Gastroenterology and Hepatology 19 (1), 136-145. e6, 2021 | 65 | 2021 |
| Increasing incidence of nonalcoholic steatohepatitis as an indication for liver transplantation in Australia and New Zealand L Calzadilla‐Bertot, GP Jeffrey, B Jacques, G McCaughan, M Crawford, ... Liver transplantation 25 (1), 25-34, 2019 | 55 | 2019 |
| Impaired glucose metabolism increases risk of hepatic decompensation and death in patients with compensated hepatitis C virus-related cirrhosis L Calzadilla-Bertot, E Vilar-Gomez, A Torres-Gonzalez, M Socias-Lopez, ... Digestive and Liver Disease 48 (3), 283-290, 2016 | 47 | 2016 |
| ABIDE: an accurate predictive model of liver decompensation in patients with nonalcoholic fatty liver‐related cirrhosis L Calzadilla‐Bertot, E Vilar‐Gomez, VWS Wong, M Romero‐Gomez, ... Hepatology 73 (6), 2238-2250, 2021 | 29 | 2021 |
| Viusid, a nutritional supplement, increases survival and reduces disease progression in HCV-related decompensated cirrhosis: a randomised and controlled trial EV Gomez, YS Rodriguez, AT Gonzalez, LC Bertot, EA Soler, YM Perez, ... BMJ open 1 (2), e000140, 2011 | 28 | 2011 |
| Validación de técnica inmunoquímica para detección de sangre oculta en heces OM Hano García, M Castellanos Gutiérrez, L Calzadilla Bertot, ... Revista Cubana de Investigaciones Biomédicas 33 (1), 19-33, 2014 | 16 | 2014 |
| Application of a biochemical and clinical model to predict individual survival in patients with end-stage liver disease EV Gomez, LC Bertot, BG Oramas, EA Soler, RL Navarro, JD Elias, ... World Journal of Gastroenterology: WJG 15 (22), 2768, 2009 | 16 | 2009 |
